Introduction
============

How different molecules and signaling pathways work together to build the intricate and precisely patterned structure of the brain is not yet clear. The thalamus is a complex of neuronal nuclei relaying sensory input to the cortex. It develops from the neuroepithelium of the caudal diencephalon also known as alar portion of p2 (Puelles et al., [@B72]; Puelles and Rubenstein, [@B73]), which generates five masses of tissue or pronuclei which further differentiate into thalamic nuclei gradually building a complex nested structure (Rose, [@B79]; Jones, [@B39]). Its development is a model of the formation of an intricate, three-dimensional brain region from a two-dimensional neuroepithelium.

The *Sonic hedgehog* (*Shh*) signaling pathway is essential for thalamic development (Kiecker and Lumsden, [@B44]; Vieira et al., [@B103]; Scholpp and Lumsden, [@B88]). Shh is a secreted morphogen conferring fate specification through a concentration gradient (Ericson et al., [@B20]; Jessell, [@B38]; Dessaud et al., [@B18]).

The Shh pathway is very complex, including several steps -- posttranslational modifications, release of Shh to the extracellular space through a unique mechanism, regulation of Shh spread, and gradient formation through binding to several membrane-bound proteins and to a multipart receptor system as well as intricate intracellular signal transduction; each of these steps depends on the cooperation of a large number of ancillary proteins (Ingham and McMahon, [@B33]; Ingham and Placzek, [@B34]; Dessaud et al., [@B18]).

The Shh protein gradient is interpreted by the progenitor cells through regulation of the activity of zinc-finger transcription factor cubitus interruptus (Ci) in *Drosophila* (Methot and Basler, [@B60]) or its vertebrate homologs, the Gli transcription factors Gli1, Gli2, and Gli3 (Hui et al., [@B31]; Lee et al., [@B48]; Ruiz i Altaba, [@B80]). While Ci can act as a transcriptional activator or, after proteolytic cleavage, as a repressor (reviewed in Jacob and Briscoe, [@B36]), the functions of each of the three Gli as activator or repressor vary between species and between CNS regions inside the same species.

In particular, Gli1 and Gli2 exert some overlapping functions but also play some distinctive roles depending on animal species and organ. For instance, in the mouse, Gli2 is an Hh-dependent activator of the Hh response in the nervous system and in the limbs as well as in the lungs; it is also essential for early development (Mo et al., [@B62]; Ding et al., [@B19]; Matise et al., [@B57]; Motoyama et al., [@B63]). In contrast, although transcription of *Gli1* is indeed upregulated by Hh (and Gli1 can activate the Hh response), it is not required for neural patterning or early development (Park et al., [@B69]). Then again, Gli1 and Gli2 have overlapping activator roles as indicated by the fact that Gli1-mediated activation can rescue the Gli2-deficient phenotype in mouse (Bai and Joyner, [@B5]).

In the zebrafish, as opposed to the mouse, Gli1 is the major activator downstream of Hh while Gli2 shows activator and repressor roles in different regions of the embryo (Karlstrom et al., [@B42]). While zebrafish deficient in *Gli1* show an important neural phenotype, *Gli2* deficiency causes only small alterations in this species (Karlstrom et al., [@B42]). In agreement, experiments overexpressing Gli proteins in *Xenopus* embryos also suggest that Gli1 is a transcriptional activator while Gli2 can behave as both activator and repressor (Ruiz i Altaba, [@B80]; Mullor et al., [@B65]).

Whereas the roles of Gli1 and Gli2 are phylogenetically divergent, the dual role of Gli3 as repressor as well as weak activator, however, seems conserved in fish and mouse (Tyurina et al., [@B102]). Finally, although the functions carried out by individual Gli proteins differ between species, within a given species there is significant functional equivalency between Gli family members.

In the mouse, Gli2 and Gli3 are activated directly by Shh signaling, and they in turn activate transcription of *Gli1* (Dai et al., [@B17]; Sasaki et al., [@B85]; Park et al., [@B69]). Gli2 is the major activator downstream of Shh, Gli1 is also an activator, and Gli3 exists as activator (Gli3A) and, after proteasome-mediated truncation, as repressor (Gli3R); the formation of Gli3R is negatively regulated by Shh (Bai and Joyner, [@B5]; Bai et al., [@B4], [@B6]; Persson et al., [@B71]; Nguyen et al., [@B67]; Stamataki et al., [@B93]; Tyurina et al., [@B102]). Since Shh attenuates the formation of Gli3R, the Shh gradient results in an opposite gradient of Gli3 repressor activity (Persson et al., [@B71]; Bai et al., [@B6]). In this way, the outcome of the activation of the Shh pathway is the induction in the developing neural tube of two gradients of transcriptional regulators with opposite polarities -- activator (high to low from ventral or medial to dorsal or lateral) and repressor (high to low from dorsal or lateral to ventral or medial; Jacob and Briscoe, [@B36]; Ruiz i Altaba et al., [@B81]).

Shh acts on the thalamic primordium after being secreted by two neuroepithelial domains -- the zona limitans and the basal midbrain (Shimamura et al., [@B90]), each with essential and specific effects (Scholpp et al., [@B89]; Vieira and Martinez, [@B104]; Jeong et al., [@B37]). In particular, the positioning of the zona limitans is under tight regulation (Scholpp et al., [@B87]). Activation of the Shh pathway in the thalamic progenitors leads to their appropriate specification and therefore to correct differentiation of thalamic nuclei (Szabo et al., [@B99]; Vue et al., [@B105]).

The Gli factors cooperate to integrate Shh and possibly other essential thalamic pathways (Zhou et al., [@B120]; Kataoka and Shimogori, [@B43]) in a region- and stage-specific manner, resulting in the specification of cell number and identity and ultimately of the size and morphology of brain regions (reviewed in Stecca and Ruiz, [@B94]). Despite numerous original contributions and reviews investigating the role of Shh in the development of the thalamus in different species, the Gli code has not been explored yet in this structure. The quantitative relation between Gli2 and Gli3 and its effects on thalamic development, however, have been approached before (Hashimoto-Torii et al., [@B26]).

Double mutants lacking Shh signaling as well as *Gli3* partially rescue the Shh null mutant phenotype in the spinal cord and ventral telencephalon (Litingtung and Chiang, [@B51]; Aoto et al., [@B1]; Persson et al., [@B71]; Rallu et al., [@B76]; Wijgerde et al., [@B109]), and so it has been postulated that Shh and Gli3R cooperate in repressing and modifying a prepattern resulting from yet unknown factors (reviewed in Ruiz i Altaba et al., [@B82]). The effects of removing both *Shh* and *Gli3* in the thalamus have not been analyzed yet.

Here we begin to assess the role of Gli factors in thalamic development by analyzing thalamic nuclear differentiation in mouse embryos deficient either in *Gli2* (Mo et al., [@B62]) or in *Gli3* (the *Extra-toes* mutant; Hui and Joyner, [@B30]; Maynard et al., [@B59]; Genestine et al., [@B23]). Furthermore, we approach the question of the reciprocally antagonistic action of Shh and Gli3 by analyzing the thalamus of a novel double mutant deficient in neuroepithelial *Shh* and in *Gli3* (termed *n-Shh/Gli3* mutant) and by loss-of-function and gain-of-function experiments in mouse embryos.

Our results suggest a combinatorial specification of each thalamic nuclear group by *Gli2* and *Gli3*. An important exception is represented by the medial and intralaminar thalamic nuclei, which develop independently of Shh signaling but are Gli3R-dependent. Finally, simultaneous deficiency in neuroepithelial Shh and Gli3 reveals a prepattern defined by *Gbx2* and *Lhx2* expression and partial specification of the medial and intralaminar nuclei, as well as an increase in size. *In utero* electroporation experiments suggest that the effects of abolishing all Gli-mediated transcriptional regulation in the thalamus are nucleus- and stage-specific.

Materials and Methods {#s1}
=====================

Mouse lines
-----------

Animals were housed and handled in ways that minimize pain and discomfort, in accordance with German animal welfare regulations and in agreement with the European Communities Council Directive (2010/63/EU). The authorization for the experiments was granted by the Regierungspräsidium Karlsruhe (state authorities) and the experiments were performed under surveillance of the Animal Welfare Officer responsible for the Institute of Anatomy and Cell Biology. To obtain embryos, timed-pregnant females of the appropriate crossings were sacrificed by cervical dislocation; the embryos were decapitated.

### *Gli2^zfd^ (Gli2 zinc finger-deleted)* mice

This *Gli2* null mutant mouse line was generated (Mo et al., [@B62]) by replacing the exons encoding for zinc fingers 3 to 5. The deletion leads to an out-of-frame mutation causing disrupted transcription from the deletion site to the 3′ end of the *Gli2* gene. This results in translation of a truncated protein unable to bind to DNA, since the zinc fingers 4 and 5 are essential for DNA binding (Pavletich and Pabo, [@B70]).

### *Gli3^Xt/+^ (extra-toes)* mouse line

Breeding pairs of heterozygotes were a kind gift from Dr. Thomas Theil (University of Edinburgh). This line carries a large deletion that inactivates the *Gli3* locus but does not affect flanking genes (Hui and Joyner, [@B30]; Maynard et al., [@B59]; Genestine et al., [@B23]).

### *n-Shh/Gli3* mutants

The double homozygous mutants for neuroepithelial *Shh* and *Gli3* were generated by crossings between *Foxb1^Cre/+^; Shh^loxP/+^* mice; and *Gli3^Xt/+^* mice. The double mutants (*Foxb1^Cre/+^; Shh^loxP/loxP^*; *Gli3^Xt/Xt^*, termed *n-Shh/Gli3* mutants) do not survive beyond birth. The *Foxb1^Cre/+^* mice show a normal phenotype (Zhao et al., [@B119], [@B118]), *Foxb1^Cre/Cre^* homozygotes were never used in this study. The *Shh^loxP/+^* conditional mutants were generated in the laboratory of Dr. Andrew McMahon (University of Harvard) and we obtained them through Jackson Labs ([www.jax.org](www.jax.org)). The *n-Shh* mutants lack all *Shh* expression in the forebrain neuroepithelium (*Foxb1^Cre/+^; Shh^loxP/loxP^*; Szabo et al., [@B98],[@B99]).

*In situ* hybridization
-----------------------

Embryos or embryonic brains were dissected, fixed in 4% paraformaldehyde, embedded in paraffin, and sectioned at 14 μm. RNA *in situ* hybridization was performed as described (Blaess et al., [@B9]).

Immunohistochemistry
--------------------

Immunofluorescent staining on sections was performed according to standard protocols. Primary antibodies were: mouse anti-Calretinin (Chemicon-Millipore, Billerica, MA, USA; MAB1568, 1:20, no unmasking, 2 days of incubation), mouse anti-neurofilament antibody 2H3 (DSHB, Iowa City; 1:100), rabbit anti-Hes1 (Chemicon AB5702; 1:100), mouse anti-NeuN (Chemicon MAB377; 1:100), rabbit anti-glial fibrillary acidic protein (GFAP) polyclonal (Chemicon AB5804; 1:100). Secondary antibodies: horse anti-mouse biotin (Vector BA2000; 1:200), Streptavidin-HRP (GE Healthcare RPN1231V; 1:100), anti-mouse IgG Alexa Fluor 488 (Invitrogen; 1:300), anti-rabbit IgG Alexa 594 (Invitrogen; 1:300).

DNA constructs for transfection
-------------------------------

We used an expression vector driven by pCAGGS (Niwa et al., [@B68]) and inserted, upstream of an internal ribosomal entry site (IRES) and either *EmGFP* (kind gift of Dr. Boris Fehse, University of Hamburg; Weber et al., [@B108]) or *tdTomato* (kind gift of Dr. Roger Y. Tsien, UCSD) as reporters, one of the following cDNAs:

1.  A mutated form of human *PTCH1* in which we deleted part (between *Mfe*I and *Nsi*I) of the second large extracellular loop (*PTCH1^Δ-loop2^*).

2.  A mutated form of mouse *Smoothened* (*mSmo*) in which we caused a G-to-T substitution by directed mutagenesis changing codon 539 from Trp to Leu (*SmoM2*; Xie et al., [@B114]).

3.  An ATG plus Kozak consensus sequence (Kozak, [@B47]) followed by the sequence encoding amino acids 471--645 of the mouse *Gli3* zinc-finger (*mGli-ZnF*).

Similar constructs have been published (Hynes et al., [@B32]; Briscoe et al., [@B12]; Cayuso et al., [@B14]).

*In utero* electroporation
--------------------------

This procedure was carried out as described (Saito and Nakatsuji, [@B84]; Saito, [@B83]) with the caveats for thalamus targeting (Kataoka and Shimogori, [@B43]; Vue et al., [@B105]; Matsui et al., [@B58]). In short, pregnant mice at E12.5 were anesthetized with a mixture of Halothane (Isoflurane, Baxter) and oxygen (0.5 l/min) administered with a Komesaroff Anaesthetic Machine. The uterus was exposed through laparotomy and the DNA solution (1 μg/μl) was injected with a glass micropipette in the ventricular system of the brain of each embryo through the uterine wall. Electric pulses were administered with a CUY21 electroporator (Nepagene, Japan; 5 square-wave pulses, 50 V, 50 ms on/950 ms off) and 5 mm tweezer electrodes. After the surgery, the embryos were allowed to develop *in utero* for 6 days and collected at E18.5 for analysis. The embryonic brains were dissected out, sectioned into 75 μm thick sections with a vibrating microtome (Compresstome VF-300, Precisionary Instruments Inc., Greenville, NC, USA) and observed and photographed with a Zeiss confocal microscope.

Statistics
----------

Statistical assessment of the electroporation data was performed with Prism 5 software (GraphPad Software, San Diego, CA, USA).

Results
=======

Regionalization defects in the *Gli* mutants
--------------------------------------------

Whole mount detection of *Gli3* mRNA on wild type embryos at E9.5 shows robust expression in the thalamic primordium (arrowhead in Figure [1](#F1){ref-type="fig"}A). Expression of *Shh* on E12.5 embryos (Figures [1](#F1){ref-type="fig"}B,C) shows an elongated zona limitans in the *Gli3^Xt/Xt^* mutant, suggesting an expansion of the thalamic primordium along the dorso-ventral axis. Expression of *Pax6*, a marker gene of the prethalamus (Stoykova and Gruss, [@B96]; Stoykova et al., [@B95]), confirms the presence of this region in the *Gli3^Xt/Xt^* mutant, although it appears dorsally elongated (Figures [1](#F1){ref-type="fig"}D,E) in keeping with the expansion of the zona limitans (Figures [1](#F1){ref-type="fig"}B,C). *Ptch1*, a diagnostic marker gene for activation of the *Shh* pathway (reviewed in Lewis et al., [@B50]), was present (arrowheads in Figures [1](#F1){ref-type="fig"}F,G), consistent with the normal expression of *Shh* in the mutant zona limitans (Figures [1](#F1){ref-type="fig"}B,C). To further explore thalamic regionalization in the Gli3*^Xt/Xt^* mutant, we examined specific thalamic regional marker gene *Dbx1* (Shoji et al., [@B92]; Ishibashi and McMahon, [@B35]), which was appropriately expressed in the *Gli3^Xt/Xt^* mutant thalamus (Figures [1](#F1){ref-type="fig"}I,J). A second thalamic marker gene, however, *Gbx2* (Miyashita-Lin et al., [@B61]; Hevner et al., [@B28]), was indeed expressed in the mutants but the expression was very reduced in extension and intensity (Figures [1](#F1){ref-type="fig"}L,M).

![**Thalamic regionalization in the Gli3Xt/Xt mutant**. **(A--E)** Whole mount *in situ* detection of markers in E9.5 **(A)** and E12.5 **(B--E)** mouse embryos, markers, and genotypes as indicated. Rostral to the left. Arrowhead in **(A)** points to the thalamic primordium. **(F--N)** *In situ* detection of marker expression on sections of E12.5 mouse embryos, markers, and genotypes as indicated. Arrowheads point to diencephalic expression. PTh, prethalamus; Th, thalamus; ZLI, zona limitans interthalamica. The brown precipitate in **(F,I,L)** corresponds to background staining. Scale bar in **(A)**, 200 μm; in **(B--N)**, 500 μm.](fnins-06-00027-g001){#F1}

Upon examination of the *Gli2* mutant embryo at the same age, however, we found severely downregulated or undetectable expression of *Ptch1* in the thalamus (Figure [1](#F1){ref-type="fig"}H), although the mRNAs of *Dbx1* and *Gbx2* were readily detected (Figures [1](#F1){ref-type="fig"}K,N).

We concluded that thalamic structures and expression of essential thalamic markers are induced in both *Gli3^Xt/Xt^* and *Gli2^zfd/zfd^* mutants

Evaluation of thalamic differentiation in the *Gli3^Xt/Xt^* and the *Gli2^zfd/zfd^* mutant thalami
--------------------------------------------------------------------------------------------------

To assess thalamic differentiation in the *Gli3^Xt/Xt^* and in the *Gli2^zfd/zfd^* mutants we performed an *in situ* analysis of specific marker expression (Figures [2](#F2){ref-type="fig"} and [3](#F3){ref-type="fig"}; Table [1](#T1){ref-type="table"}). Both mutants survive until E18.5, which was chosen as age of analysis. We used as markers several genes previously mapped to different thalamic nuclei and whose usefulness for phenotype assessment has been demonstrated (Szabo et al., [@B99]): *Calb2* (*Calretinin*; Arai et al., [@B2], [@B3]; Winsky et al., [@B112]; Frassoni et al., [@B22]), *Gbx2* (Jones and Rubenstein, [@B40]), *Lhx2* and *Ngn2* (Nakagawa and O'Leary, [@B66]), and *Cdh6* (Jones and Rubenstein, [@B40]). These results are summarized in Table [1](#T1){ref-type="table"}. To these markers we add here expression of *Hes1* (*hairy and enhancer of split 1*), a transcription factor in the Notch pathway (Kageyama et al., [@B41]), as novel marker for the ventral posterior nuclear group of the thalamus at E18.5 (Figures [4](#F4){ref-type="fig"} and [6](#F6){ref-type="fig"}; Lein et al., [@B49]). Our list is certainly not exhaustive, and the search for marker genes specific for different thalamic regions and nuclei is ongoing (Suzuki-Hirano et al., [@B97]; Yuge et al., [@B117]).

![**Thalamic differentiation in the *Gli3^Xt/Xt^* and *Gli2* mutants (1)**. *In situ* detection of Calb2 **(A--L)** and Gbx2 **(M--R)** expression on transverse sections of wild type **(A--D,M,N)**, Gli3Xt/Xt **(E--H,O,P)**, and Gli2zfd/zfd **(I--L,Q,R)** E18.5 mouse brains. Comparable rostro-caudal thalamic levels are represented side-by-side. White and black arrowheads point at comparable structures across genotypes. The dotted line in **(G)** and **(H)** delimits the mutant thalamus from more caudal structures. The outline of the section has been delineated in **(Q)**. Scale bar, 500 μm.](fnins-06-00027-g002){#F2}

![**Thalamic differentiation in the *Gli3^Xt/Xt^* and *Gli2* mutants (2)**. RNA *in situ* detection of Lhx2 **(A--I)**, Ngn2 **(J--L)**, and Cdh6 **(M--R)** expression on transverse sections of wild type **(A--C,J,M,N)**, Gli3Xt/Xt **(D--F,K,O,P)**, and Gli2zfd/zfd **(G--I,L,Q,R)** E18.5 mouse brains. Comparable rostro-caudal thalamic levels are represented side-by-side. White and black arrows point at comparable structures at comparable rostro-caudal levels across genotypes. The outline of the sections has been delineated in **(J--L)**. Scale bar, 500 μm.](fnins-06-00027-g003){#F3}

###### 

**Markers and nuclei in the wild type and *Gli3^Xt/Xt^* and *Gli2^zfd/zf^d* thalamus**.

                *Gli3^Xt/Xt^*   *Gli2^zfd/zfd^*   *n-Shh/Gli3*   
  ------------- --------------- ----------------- -------------- ------
  **CENTRAL**                                                    
  ATN           *Lhx2*          −−−               ++             −−−
                *Cdh6*          ++                ++             −−−
  VP            *Cdh6*          ++                \+             −−−
  VM            *Ngn2*          −−−               \+             −−−
  Dorsal        *Calb2*         ++                −−−            −−−
                *Cdh6*          −−−               \+             −−−
  LGN           *Ngn2*          −−−               \+             −−−
                *Cdh6*          ++                −−−            −−−
  MGN           *Calb2*         ++                −−−            −−−
                *Gbx2*          −−−               \+             −−−
                *Lhx2*          −−−               \+             −−−
  Medial        *Calb2*         \+                +++            ++++
                *Gbx2*          \+                +++            ++++
                *Lhx2*          \+                +++            ++++

*The symbol "+++" denotes normal expression; "++" and "+" denote reduced and very reduced intensity of expression, respectively; "++++" denotes expression more intense or over a larger area than in the wild type; and "−−−" denotes loss of expression*.

![**Thalamocortical axons in the *Gli3^Xt/Xt^* and *Gli2* mutants**. **(A--C)** Antibody detection of GFAP (red) and NeuN (green) on transverse sections of E18.5 wild type **(A)**, Gli3Xt/Xt **(B)**, and Gli2zfd/zfd **(C)** thalamus. **(D--F)** Antibody detection of Hes1 (red) and neurofilaments (green) on transverse sections of E18.5 wild type **(D)**, Gli3Xt/Xt **(E)**, and Gli2zfd/zfd **(F)** thalamus. **(G--I)** Confocal mosaic images of transverse sections through the E18.5 wild type **(E)**, Gli3Xt/Xt **(B)**, and Gli2zfd/zfd **(C)** brain showing antibody detection of neurofilaments, green. Scale bars, 100 μm **(A--F)** and 500 μm **(G--I)**.](fnins-06-00027-g004){#F4}

The developing thalamic mantle layer forms five neuronal masses or pronuclei out of which the adult thalamic nuclei gradually differentiate. The pronuclei and their derivatives are: medial pronucleus (medial and intralaminar nuclei), central pronucleus (anterior and ventral nuclear groups), dorsal pronucleus (lateral and posterior nuclear groups), lateral geniculate pronucleus, and medial geniculate pronucleus (Rose, [@B79]; Jones, [@B39]). We decided to use this classification for our analysis of the mutant thalamic phenotypes.

The midline and intralaminar nuclei are severely affected in the *Gli3^Xt/Xt^* but not in the *Gli2^zfd/zfd^* mutant thalamus
-----------------------------------------------------------------------------------------------------------------------------

First, we sought to define the derivatives of the medial pronuclear group, including the medial nuclei \[mediodorsal, medioventral (or reuniens), paraventricular, paratenial, and rhomboid\] and the intralaminar nuclei (particularly the centromedial, paracentral, and centrolateral) by detecting the expression of marker genes *Calb2*, *Gbx2*, and *Lhx2*. *Calb2* shows a complex and characteristic expression pattern in this structure (Arai et al., [@B2], [@B3]; Winsky et al., [@B112]; Frassoni et al., [@B22]), which makes it useful for a general assessment of differentiation (Szabo et al., [@B99]; Figures [2](#F2){ref-type="fig"}A--D).

The *Gli3^Xt/Xt^* mutant shows a gross morphological alteration of the di-telencephalic junction (Theil et al., [@B101]; Fotaki et al., [@B21]; Rash and Grove, [@B78]) affecting all rostral and dorsal structures (Figures [2](#F2){ref-type="fig"}E,F). In contrast, *Calb2* expression was conserved in the midline (white arrows in Figures [2](#F2){ref-type="fig"}E,F) and recognizable on the basis of position and morphological traits in the medioventral nucleus (MV in Figure [2](#F2){ref-type="fig"}F), in the dorsal group (LP and PO, black arrows in Figures [2](#F2){ref-type="fig"}C,G) and in the medial geniculate nucleus (MG, white arrow in Figure [2](#F2){ref-type="fig"}H).

In the *Gli2* mutant, the thalamus seemed of normal morphology but of reduced size and the size reduction was most prominent in caudal sections (Figures [2](#F2){ref-type="fig"}I--L). *Calb2* was expressed in the medial group rostrally following a somewhat reduced normal pattern (Figures [2](#F2){ref-type="fig"}I,J). This marker however disappeared at more caudal levels and was not found in the dorsal group or in the medial geniculate (Figures [2](#F2){ref-type="fig"}K,L). We confirmed these results by antibody staining for calretinin (not shown).

*Gbx2* labels the medial and intralaminar nuclei very specifically in the wild type (Figure [2](#F2){ref-type="fig"}M). Its expression is severely reduced but can still be detected in a midline domain in the *Gli3^Xt/Xt^* mutant (arrow in Figure [2](#F2){ref-type="fig"}O). In the *Gli2^zfd/zfd^* mutant (arrow in Figure [2](#F2){ref-type="fig"}Q), on the contrary, *Gbx2* expression is strong and specific in this nuclear group.

*Lhx2* is also expressed characteristically by the derivatives of the medial pronucleus (white arrows in Figures [3](#F3){ref-type="fig"}A,B). Its expression is present only in a small, compact, medial and dorsal structure in the *Gli3^Xt/Xt^* mutant (arrows in Figures [3](#F3){ref-type="fig"}D,E). The *Gli2^zfd/zfd^* mutant shows robust and appropriate expression of *Lhx2* (white arrows in Figures [3](#F3){ref-type="fig"}G,H) indicating complete preservation of the medial and intralaminar nuclei.

We concluded that derivatives of the medial pronucleus (midline and intralaminar nuclei), are drastically altered in the *Gli3^Xt/Xt^* mutant but show essentially normal marker expression and size in the *Gli2^zfd/zfd^* mutant.

The central and dorsal pronuclei are differentially affected in the *Gli3^Xt/Xt^* and the *Gli2^zfd/zfd^* mutants
-----------------------------------------------------------------------------------------------------------------

We used the markers *Lhx2*, *Ngn2*, and *Cdh6* in order to explore the anterior and ventral thalamic nuclear groups, derivatives of the central pronucleus. The anterior thalamic nuclei were labeled by *Lhx2* (black arrow in Figure [3](#F3){ref-type="fig"}A) and by *Cdh6* (white arrow in Figure [3](#F3){ref-type="fig"}M). In the *Gli3^Xt/Xt^* mutant, they lost *Lhx2* expression (Figure [3](#F3){ref-type="fig"}D) but are still labeled by *Cdh6* (white arrow in Figure [3](#F3){ref-type="fig"}O). The *Gli2^zfd/zfd^* mutant showed expression of the two markers in a rostral structure clearly identifiable as part of the anterior thalamic complex (*Lhx2*, black arrow in Figure [3](#F3){ref-type="fig"}G; *Cdh6*, white arrow in Figure [3](#F3){ref-type="fig"}Q).

Specific *Ngn2* expression in the ventromedial nucleus (white arrow in Figure [3](#F3){ref-type="fig"}J) was absent from the *Gli3^Xt/Xt^* mutant (Figure [3](#F3){ref-type="fig"}K) but present, very reduced in extension and intensity, in the *Gli2^zfd/zfd^* mutant (white arrow in Figure [3](#F3){ref-type="fig"}L). Finally, we detected *Cdh6*, a specific marker of the ventral posterior nuclei (white arrow in Figure [3](#F3){ref-type="fig"}N), in both mutants (white arrows in Figures [3](#F3){ref-type="fig"}P,R).

Derivatives of the dorsal pronucleus (lateral and posterior thalamic nuclei) can be labeled by *Calb2* (black arrow in Figure [2](#F2){ref-type="fig"}C) or *Cdh6* (arrowhead in Figure [3](#F3){ref-type="fig"}N) expression. The *Gli3^Xt/Xt^* mutant showed *Calb2* expression in structures reasonably identifiable as the lateral and posterior nuclei (LP, PO, black arrow in Figure [2](#F2){ref-type="fig"}G), but no *Cdh6* expression in the appropriate position (Figure [3](#F3){ref-type="fig"}P). The *Gli2^zfd/zfd^* mutant showed only expression of *Cdh6* in the possible lateral group (arrowhead in Figure [3](#F3){ref-type="fig"}R).

Both mutants express some, but not all of the specific markers for thalamic nuclei derived from the central and dorsal pronuclei. We concluded that differentiation of the central and dorsal pronuclei is altered in both mutants, albeit with differences in the effects and severity.

The lateral and medial geniculate nuclei
----------------------------------------

To investigate the differentiation of the lateral geniculate nucleus (dorsal) we used markers *Ngn2* (black arrow in Figure [3](#F3){ref-type="fig"}J) and *Cdh6* (black arrow in Figure [3](#F3){ref-type="fig"}N). We were able to detect only *Cdh6* in the lateral geniculate of the *Gli3^Xt/Xt^* mutant (black arrow in Figure [3](#F3){ref-type="fig"}P). The *Gli2^zfd/zfd^* mutant, on the contrary, expressed *Ngn2*, although at very low intensity, in the lateral geniculate (black arrow in Figure [3](#F3){ref-type="fig"}L) but no trace of *Cdh6* (Figure [3](#F3){ref-type="fig"}R).

The medial geniculate is labeled by expression of *Calb2* (MG, white arrow in Figure [2](#F2){ref-type="fig"}D), *Gbx2* (white arrow in Figure [2](#F2){ref-type="fig"}N), *Lhx2* (white arrow in Figure [3](#F3){ref-type="fig"}C), and *Cdh6* (Szabo et al., [@B99]). We discarded *Cdh6* as a useful marker for this structure since it labels also the lateral geniculate nucleus, which is contiguous to the medial along the antero-posterior axis and could cause confusion. Only *Calb2* was expressed in the appropriate caudal level of the *Gli3^Xt/Xt^* mutant thalamus (white arrow in Figure [2](#F2){ref-type="fig"}H). The *Gli2^zfd/zfd^* mutant showed no *Calb2* expression in the appropriate region. *Gbx2* (white arrow in Figure [2](#F2){ref-type="fig"}R) and *Lhx2* (white arrow in Figure [3](#F3){ref-type="fig"}I) were however present in the medial geniculate (although very reduced in extension and intensity).

In summary, the medial and intralaminar nuclei (medial pronucleus) showed a remarkable degree of preservation in the *Gli2^zfd/zfd^* mutant but were severely affected in the *Gli3^Xt/Xt^* mutant. Each of the other pronuclei (dorsal, central, lateral geniculate, medial geniculate) expressed at least one of its characteristic markers in both mutants. The loss or preservation of specific marker expression was often complementary between the *Gli2^zfd/zfd^* and the *Gli3^Xt/Xt^* mutant (Table [1](#T1){ref-type="table"}). Finally, the *Gli2^zfd/zfd^* mutant thalamus was of reduced size and, the *Gli3^Xt/Xt^* mutant seemed to be larger than in the wild type, in agreement with previous morphometric work (Aoto et al., [@B1]).

Thalamocortical efferents in the *Gli* mutants
----------------------------------------------

In addition to our marker analysis with *in situ* hybridization we used antibodies against pan-neuronal marker protein NeuN (Wolf et al., [@B113]; green in Figures [4](#F4){ref-type="fig"}A--C) as well as against glial marker GFAP (arrow, red labeling in Figures [4](#F4){ref-type="fig"}A--C) in order to ascertain that the *Gli3^Xt/Xt^* as well as the *Gli2^zfd/zfd^* mutant thalamus are able to appropriately express general differentiation markers, as was the case (Figures [4](#F4){ref-type="fig"}A--C).

Essential to thalamic function are the thalamocortical efferents, whose development is a complex process depending on the appropriate fate specification of thalamic neurons by a cascade of key transcription factor genes (Lopez-Bendito and Molnar, [@B52]). Exploring the status of these efferents can provide important information about the degree of thalamic differentiation.

The thalamocortical axons of the somatosensory pathway originate from the ventral posterior complex (ventral postero-medial and ventral postero-lateral nuclei). At E18.5, transcription factor gene *Hes1* is expressed in a single, well-delimited thalamic region (Lein et al., [@B49]) which we surmised, because of its localization, could be the ventral posterior group. Antibody detection of Hes1 on wild type E18.5 thalamus showed staining of the ventral posterior complex (red in Figure [4](#F4){ref-type="fig"}D), and neurofilament co-detection demonstrated as expected thalamocortical axons streaming out of the complex (asterisk in Figure [4](#F4){ref-type="fig"}D). In the *Gli3^Xt/Xt^* mutant, *Hes1* was also expressed by a nuclear group (Figure [4](#F4){ref-type="fig"}E) extending very numerous axons into the direction of the telencephalon (asterisk in Figure [4](#F4){ref-type="fig"}E). The *Gli2^zfd/zfd^* mutant, however, showed weak and spatially reduced *Hes1* expression in the region of the ventral posterior complex. A reduced number of axons originated in this area (asterisk in Figure [4](#F4){ref-type="fig"}F).

We then used stitching of multiple confocal images to analyze the broad pattern of axons connecting thalamus and telencephalon in Gli2 and Gli3 null mutants (Figures [4](#F4){ref-type="fig"}G--I). Thalamocortical axons were revealed as much in the wild type brain (arrowhead in Figure [4](#F4){ref-type="fig"}G) as in the *Gli3^Xt/Xt^* (arrowhead in Figure [4](#F4){ref-type="fig"}H) and the *Gli2^zfd/zfd^* (arrowhead in Figure [4](#F4){ref-type="fig"}I) mutants. However there were clear differences between the mutants and between each mutant and the wild type. In the wild type, the thalamocortical axons form a well-developed layer in the cortex (double arrowhead in Figure [4](#F4){ref-type="fig"}G). The *Gli3^Xt/Xt^* mutant seems to send very large numbers of axons in the general direction of the telencephalon, but at E18.5 they had not been able to proceed further into this region (Figure [4](#F4){ref-type="fig"}H), consistent with the severe defects in the cortex of the *Gli3^Xt/Xt^* (Theil et al., [@B101]; Theil, [@B100]). The *Gli2^zfd/zfd^* mutant thalamus sends only very sparse thalamocortical axons, resulting in a thin labeled axonal layer in the cortex (double arrowhead in Figure [4](#F4){ref-type="fig"}I).

The thalamus of the double *Shh-Gli3^Xt/Xt^* mutant
---------------------------------------------------

Gli3R and Shh have reciprocally antagonistic functions (Litingtung and Chiang, [@B51]), and there is evidence that, in the telencephalon, deficit in both of them results in a phenotype closer to the wild type than that resulting from the mutation of each gene alone (Rallu et al., [@B76]). The implication is that other factors, acting earlier, are able to provide the telencephalon with a pattern (the so-called "prepattern"). During normal development, the combined action of *Shh* and *Gli3* would later eliminate this prepattern and impose a new pattern (i.e., the normal thalamic pattern). Only when both *Shh* and *Gli3* are experimentally inactivated is the prepattern uncovered (Ruiz i Altaba et al., [@B82]; Gutin et al., [@B24]; Hebert and Fishell, [@B27]).

Here we attempted for the first time to uncover such a possible "prepattern" in the thalamus by generating mice lacking *Shh* expression in the forebrain neuroepithelium as well as Gli3 expression. In previous work, we used a Cre-lox strategy to generate a mouse mutant lacking *Shh* expression in the forebrain neuroepithelium (the *n-Shh* mutant mouse; Szabo et al., [@B98],[@B99]). Here we crossed the *Foxb1^Cre/+^*, the *Shh^loxP/loxP^*, and the *Gli3^Xt/+^* mouse lines to obtain homozygous null mutant embryos for neural *Shh* as well as *Gli3* (*Foxb1^Cre/+^*; *Shh^loxP/loxP^*; *Gli3^Xt/Xt^*, in what follows called "double mutants" or *n-Shh/Gli3* mutants; see [Materials and Methods](#s1){ref-type="sec"} for details). These embryos are not born alive but can usually be collected at E18.5. At this age, the double mutant shows (Figure [5](#F5){ref-type="fig"}) a large thalamic primordium lacking characteristic dorsal structures (diencephalic roof and epithalamus-habenula). The lumen of the third ventricle, widened dorsally, correlates with the absence of the prethalamus (which is also absent in the *n-Shh* mutant; Szabo et al., [@B99]).

![**Thalamic differentiation in the double *n-Shh/Gli3* mutant**. *In situ* detection of Calb2 **(A--F)**, Lhx2 **(G--L)**, Gbx2 **(M--P)**, and Cdh6 **(Q--T)** expression on transverse sections of wild type **(A--C,G--I,M,N,Q,R)** and n-Shh/Gli3 **(D--F,J--L,O,P,S,T)** E18.5 mouse brains. Comparable rostro-caudal thalamic levels are represented side-by-side. White arrows and black arrows point at comparable structures across genotypes. The outline of the section has been delineated in **(O,P)**. Scale bar, 500 μm.](fnins-06-00027-g005){#F5}

We then explored thalamic differentiation in the wild type and double mutant by using as markers *Calb2* (Figures [5](#F5){ref-type="fig"}A--F), *Lhx2* (Figures [5](#F5){ref-type="fig"}G--L), *Gbx2* (Figures [5](#F5){ref-type="fig"}M--P), and *Cdh6* (Figures [5](#F5){ref-type="fig"}Q--T). As for *Ngn2*, we were not able to detect expression of this gene in the thalamus of the double mutant at all (not shown). A striking finding was a wide ventral band of *Calb2* (white arrows in Figures [5](#F5){ref-type="fig"}D--F), *Lhx2* (white arrows in Figures [5](#F5){ref-type="fig"}J--L), and *Gbx2* (white arrow in Figure [5](#F5){ref-type="fig"}O) expression extending along most of the rostro-caudal length of the double mutant thalamic primordium. Since these three markers are characteristic for the medial pronucleus (medial and intralaminar nuclei), and given the anatomical localization of the expression area, this result suggests that at least the ventral part of the medial pronucleus is present, and largely expanded, in the double mutant.

In addition, we noticed the presence of two small, paired, dorsal domains of weak marker expression that should correspond to two dorsal stripes visible with each of the four probes used, *Calb2* (arrowheads in Figures [5](#F5){ref-type="fig"}D--F), *Lhx2* (arrowheads in Figure [5](#F5){ref-type="fig"}L), *Gbx2* (Figure [5](#F5){ref-type="fig"}P), and *Cdh6* (arrowheads in Figures [5](#F5){ref-type="fig"}S,T). No other thalamic nucleus or structure could be recognized in the double mutant thalamus.

Furthermore, we determined that the double mutant thalamus expresses NeuN, a general marker of neurons, as well as GFAP, a marker of radial glia (Figure [6](#F6){ref-type="fig"}A)

![**Axonal tracts in the double *n-Shh/Gli3^Xt/Xt^* mutant. Antibody detection of markers on transverse sections through the diencephalon of the *n-Shh/Gli3^Xt/Xt^* double mutant brain at E18.5**. **(A)** NeuN (green) and GFAP (red). **(B,C)** Neurofilaments \[green in **(B,C)**\] and Hes1 \[red in **(B)**\]. **(C)** Shows a confocal mosaic, **(B)** shows a detail of **(C)** under higher magnification. Scale bars 100 μm **(A)**, 200 μm **(B)**, and 500 μm **(C)**.](fnins-06-00027-g006){#F6}

Thalamocortical axons in the *n-Shh/Gli3* double mutant
-------------------------------------------------------

Next, we investigated the development of thalamocortical axons in the double-mutant through detection of neurofilaments and of Hes1 protein (see above, Figures [2](#F2){ref-type="fig"} and [3](#F3){ref-type="fig"}). Hes1 was weakly expressed in the region giving rise to the presumed thalamocortical axons (Figure [6](#F6){ref-type="fig"}B). We were able to detect axons, although not very numerous, extending from the thalamic primordium in the direction of the telencephalon (arrowhead in Figure [6](#F6){ref-type="fig"}C). The telencephalon (including the cortex) of the double mutants showed a very abnormal phenotype, and the axons seemed unable to enter the telencephalic primordium (Figure [6](#F6){ref-type="fig"}C).

These results provide evidence that, in the absence of *Gli3* expression and neuroepithelial *Shh* expression there is some appropriate thalamic differentiation.

An approach to the *Shh* vs *Gli3* reciprocal antagonism through *in utero* manipulation of the *Shh* pathway
-------------------------------------------------------------------------------------------------------------

The increase in size obvious in the double mutant thalamus indicated that an abnormal surge in proliferation, independent from neuroepithelial *Shh*, had been unleashed by the simultaneous deficiencies in neuroepithelial *Shh* and in *Gli3*. The most striking size increase corresponded to the most differentiated part of the double mutant thalamus, a wide ventral domain which could correspond to some of the nuclei of the medial group (Figure [6](#F6){ref-type="fig"}). Since we could not recognize any other thalamic nucleus, we reasoned that a surge in proliferation activity could specifically affect the progenitors of the medial group at an early stage, when progenitor pools are still expanding, rather than later, when the actual neurons are generated (E12.7--E14.4; Bayer and Altman, [@B7]; Clancy et al., [@B16]). Therefore, we wanted to know if a late abolition of neuroepithelial Shh and Gli3 activity would also cause an increase in proliferation.

We approached this question by experimentally altering the Shh pathway in the progenitors of the dorsal lateral geniculate nucleus (which develops early) on wild type embryos developing *in utero*. The lateral geniculate nucleus was chosen as a candidate since it belongs to a different pronuclear group developing comparatively early (E11.9--E12.7; Bayer and Altman, [@B7]; Clancy et al., [@B16]) but still late enough that it can be experimentally approached *in utero*.

In order to establish a basis for the interpretation of our results, we first performed experiments transfecting DNA constructs that either block or constitutively activate the Shh pathway activity cell autonomously (see below). Since we transfect a 2:1 mixture of green (control):red (experimental) constructs, the effect of any experimental construct on proliferation can be measured by the ratio between green fluorescent cells and red fluorescent cells that result from the transfection. If the experimental construct has no effect at all, 100% of labeled cells will express the green reporter and 50% of them would express additionally the red reporter (since they are transfected with a 2:1 ratio); since green plus red fluorescence will appear yellow, we would expect 50% of all labeled cells to be green fluorescent (expressing only *EmGFP*) and 50% to be yellow fluorescent (expressing *EmGFP*- and *tdTomato*). Any increase or decrease in the proportion of red reporter-expressing cells (yellow) vs only green reporter-expressing cells will indicate increase or decrease in proliferation induced by the corresponding experimental construct.

Blocking *Shh* signaling in the developing lateral geniculate nucleus
---------------------------------------------------------------------

We first used *in utero* electroporation to transfect a 2:1 mixture of plasmids carrying either the reporter gene *EmGFP* (green) or a mutated form of the *Shh* receptor *Ptch1* (*Ptch1^Δloop2^*) plus reporter gene *tdTomato* (red) into the thalamus of E12.5 embryos. Both constructs included a powerful constitutive promoter (see [Materials and Methods](#s1){ref-type="sec"} for details). Transfection of this mutated form of *Ptch1* blocks *Shh* signaling cell-autonomously (Briscoe et al., [@B12]). The transfected embryonic brains were collected and sectioned after 6 days survival *in utero* (E18.5) and labeled cells were counted in the region of the lateral geniculate nucleus (five embryos, nine sections; Figures [7](#F7){ref-type="fig"}A--C).

![**Loss of all *Gli* activity reduces proliferation of lateral geniculate progenitors**. **(A,B,D,E,G,H)** Confocal images of the E18.5 lateral geniculate nucleus in representative transverse Compresstome sections showing expression of green fluorescent reporter (top row) or both green and red fluorescent reporter (middle row) after in utero electroporation transfection at E12.5 of plasmid constructs as indicated. Cells expressing both the control and experimental construct are yellow in **(B,E,H)**. White arrowheads in **(H)** indicate double-labeled (yellow) cells. **(C,F,I)** Cell counting histograms (mean ± SD) after the corresponding transfections; n.s., non-significant.](fnins-06-00027-g007){#F7}

This experiment yielded ca. 92.40% green cells (carrying the control construct expressing *EmGFP*) and only 5.60% yellow cells (carrying both the *EmGFP* control construct plus the *Ptch1^Δloop2^* construct with red reporter *tdTomato*) in the lateral geniculate nucleus (a small percent of the labeled cells could not be unequivocally attributed red or yellow color). This result confirms that cell-autonomous inactivation of the *Shh* pathway leads to decreased proliferation (Ishibashi and McMahon, [@B35]; Szabo et al., [@B99]). Additionally, an increase in Gli3R in absence of Shh signaling could increase cell death.

Constitutive activation of *Shh* signaling in the developing lateral geniculate nucleus
---------------------------------------------------------------------------------------

Next, we performed similar experiments using as experimental plasmid a DNA construct carrying *SmoM2*, a mutated form of the gene encoding Smoothened, a transmembrane protein essential for *Shh* signaling (Xie et al., [@B114]; Hynes et al., [@B32]). Expression of *SmoM2* activates the *Shh* pathway constitutively (Hynes et al., [@B32]). Transfection of *SmoM2* (four embryos, six sections) resulted in non-significant difference between the number of cells expressing only the control reporter (green cells) and the number of cells expressing both the control reporter and the red (experimental) reporter (yellow cells; Figures [7](#F7){ref-type="fig"}D--F). This is the result that we would expect if constitutive activation of the Shh pathway at E12.5 had no effect on progenitor proliferation (see above).

Blocking all transcriptional regulation by Gli proteins in the developing lateral geniculate nucleus
----------------------------------------------------------------------------------------------------

In order to mimic the effect of the double deficiency in neuroepithelial *Shh* and in *Gli3*, we generated DNA constructs carrying a mutated form of *Gli3* containing only the DNA-binding zinc-finger-domain (*Gli-ZnF*; Cayuso et al., [@B14]). Expression of *Gli-ZnF* results in the synthesis of a truncated Gli protein such that it specifically binds to DNA blocking all Gli-mediated transcriptional activation and repression; therefore, it can be considered the equivalent of a simultaneous loss of Shh and Gli3 (Cayuso et al., [@B14]).

This experiment (two embryos, five sections) resulted in 83.0% of green cells and 16.0% of yellow cells (Figures [7](#F7){ref-type="fig"}G--I). This indicates that blocking all GliA and GliR activity at E12.5 in the lateral geniculate (dorsal) does not increase proliferation at all (as would be expected on the basis of the *n-Shh/Gli3* mutant phenotype), but rather decreases it significantly.

Discussion
==========

We have attempted to clarify the Gli code as it applies to thalamic development in the mouse. Our conclusions are based on the analysis of mutant phenotypes, among them a novel double mutant, and on *in utero* experiments on wild type background. Although this approach is straightforward, several caveats apply to our interpretation of the data.

First of all, we use gene marker expression to determine if a phenotype is altered. One possible concern here is that we use only a tiny fraction of all existing specific marker genes. A full description of all specific nuclear markers for the thalamus is not yet available; it is also possible that the number of markers would be too large to be of practical interest. All things considered, though, the fact that the expression of some specific genes is altered is enough to state that the development of a specific nucleus is altered. If some nuclei are more altered than others, or if other markers would have shown a more complex phenotype, are valid questions that we cannot approach in this contribution.

Additionally, in our paper we do not address which genes or cellular processes act downstream of the Gli proteins in order to control thalamic development. While this is a very interesting field of inquiry for the future, it is obviously beyond the scope of this study. Finally, since the *Gli3^Xt/Xt^* mutants and the *n-Shh/Gli3* double mutants die before birth, here we do not analyze the adult thalamus -- however, it is in principle possible that the defective phenotypes we describe could have been compensated somehow later in development.

Functions of Gli factors downstream of Shh in the thalamus
----------------------------------------------------------

Expression of *Ptch1* is upregulated in cells that receive high levels of Shh and in which GliA is induced, and it is considered diagnostic of activation of the Shh pathway (reviewed in Lewis et al., [@B50]). We have not been able to detect *Ptch1* expression in the *Gli2^zfd/zfd^* mutant mice at E12.5, indicating that *Ptch1* expression is not induced or that expression levels are too low to be detected (Figure [1](#F1){ref-type="fig"}). We are not aware of other publications analyzing *Ptch1* expression in the *Gli2^zfd/zfd^* thalamus. In any case, the fact that *Ptch1* is downregulated only in the *Gli2^zfd/zfd^* but not in the *Gli3^Xt/Xt^* thalamus indicates that Gli2 is the main activator downstream of Shh in this structure. This suggests that the main functions of the elements of the Shh pathway are the same in the thalamus as the ones classically described in the spinal cord (Matise et al., [@B57]; Litingtung and Chiang, [@B51]).

Intriguingly, *Gli1* expression, another readout for Shh signaling, is very reduced but still detectable in the *Gli2^zfd/zfd^* mutants in the dorsal diencephalon at E10.5 (S. Blaess, unpublished results). This is remarkable, since *Ptch1* and *Gli1* are both readouts for high levels of *Shh* signaling. It is possible that the loss of Gli2 can be compensated by Gli3A only at early embryonic stages (before E12.5) but not late, or perhaps *Gli1* is expressed at slightly higher levels of in the mutants, that are easier to detect.

The *Gli2^zfd/zfd^* thalamic phenotype
--------------------------------------

The *Gli2^zfd/zfd^* mutant thalamus is remarkably reduced in size and has a reduced marker expression. This agrees with the function of Gli2 as the major activator downstream of Shh. The fact that the thalamus is only reduced and not completely absent in the *Gli2^zfd/zfd^* mutants is most likely due to a compensatory role of Gli3A. In the absence of Gli2, the activator form of Gli3 can be induced by high levels of Shh signaling, and in combination with Gli1A, Gli3 can rescue at least partially the Gli2 deficiency (Bai et al., [@B6]). However, Gli3A is only a weak activator (Dai et al., [@B17]; Shin et al., [@B91]; Litingtung and Chiang, [@B51]; Motoyama et al., [@B64]; Bai et al., [@B6]) and cannot completely restore proliferation or differentiation. This is confirmed by the poor development of the thalamocortical projection in the *Gli2^zfd/zfd^* thalamus.

The thalamic primordium is exposed to Shh secreted by a large neuroepithelial domain comprised by a rostral, transverse portion (the zona limitans) and a ventral, longitudinal portion (the basal midbrain; Shimamura et al., [@B90]). Both portions are important to create a zone of very high Shh signaling ensuring proper specification of thalamic progenitors (Jeong et al., [@B37]). The curved shape of this rostral-plus-ventral domain is also observed in the immediately adjacent domain of *Ptch1* expression that is an indicator of high levels of Shh signaling and Gli2A activity (Figures [1](#F1){ref-type="fig"}F,G; see also Lein et al., [@B49]). Therefore, we would expect the most severe *Gli2^zfd/zfd^* phenotype rostro-ventrally, i.e., in the area of highest Shh signaling. This is however masked by the good preservation of the derivatives of the medial pronucleus, i.e., the medial and intralaminar nuclei, whose development is not affected in mutants deficient in neuroepithelial *Shh* either (Szabo et al., [@B99]; see below). These nuclei are of normal size in the *Gli2^zfd/zfd^* mutant and express their characteristic markers *Calb2*, *Gbx2*, and *Lhx2*. Since they occupy the central part and the rostral 2/3 of the thalamus, their good preservation in the mutant causes the misleading impression that the *Gli2^zfd/zfd^* thalamus is particularly small caudally.

The *Gli3^Xt/Xt^* thalamic phenotype
------------------------------------

The *Gli3^Xt/Xt^* mutant thalamus shows alterations in size and AP patterning. Specifically, the rostral--dorsal part of the mutant thalamus is severely altered by the loss of di-telencephalic junction (Theil et al., [@B101]; Fotaki et al., [@B21]; Quinn et al., [@B75]; Rash and Grove, [@B78]). The thalamus of this mutant is larger than the wild type thalamus (Aoto et al., [@B1]), suggesting that in this brain region Gli3 represses proliferation or survival. In the dorsal midbrain region, Gli3R is essential for restricting growth to a normal level and for correct AP patterning in the mid-hindbrain region (Blaess et al., [@B10]). The effect of Gli3 on growth is very much context dependent (Yu et al., [@B115]) and, for example, the cerebellum is reduced in size in *Gli3^Xt/Xt^* mutants (Blaess et al., [@B10]).

Additionally, there are alterations of nuclear specification: the role of Gli3R in thalamic differentiation affects specific genes in specific nuclei (Table [1](#T1){ref-type="table"}). This, together with the often complementary loss of specific markers in the *Gli3^Xt/Xt^* and the *Gli2^zfd/zfd^* thalamus is consistent with a "GliA/R code" in the thalamus which specifies every nucleus on the basis of GliA/R ratios determined by local Shh signaling levels (Hashimoto-Torii et al., [@B26]). That the thalamocortical axons do not enter the telencephalon can also be due to specific alteration in telencephalic differentiation in the absence of *Gli3* (Magnani et al., [@B53]).

The alterations in the *Gli3^Xt/Xt^* thalamus are likely due to loss of Gli3R rather than loss of Gli3A, since at the high levels of Shh signaling that result in Gli3A formation, Gli2A is also strongly upregulated and could compensate for the loss of Gli3A (Bai et al., [@B6]). This is also evident in the *Ptch1* expression in the *Gli3^Xt/Xt^* thalamus, which is not reduced in the mutants. Other studies emphasize the importance of the repressor function of Gli3 -- in mouse mutants with reduced production of Gli3R (not Gli3A), cortical defects ensue similar to those found in the *Gli3^Xt/Xt^* mutant (Willaredt et al., [@B110]; Besse et al., [@B8]; Wilson et al., [@B111]). Furthermore, Gli3R is required to specify V0 interneurons in the ventral spinal cord (Persson et al., [@B71]) as well as for fate specification in cortical neurons (Wang et al., [@B107]) and for cerebellar foliation (Blaess et al., [@B10]; Kim et al., [@B45]). The Gli3 repressor function is also essential for limb (Hill et al., [@B29]), kidney (Cain et al., [@B13]), and thymus specification (Hager-Theodorides et al., [@B25]).

The Gli3 repressor function is essential for the development of the medial and intralaminar nuclei
--------------------------------------------------------------------------------------------------

We have previously shown that the derivatives of the medial pronucleus (the medial and intralaminar nuclei) are specifically lost in *Gbx2* mutants (Szabo et al., [@B99]). Early *Gbx2* expression defines the entire thalamic neuroepithelium (Martinez-de-la-Torre et al., [@B55]; Hashimoto-Torii et al., [@B26]), and the whole thalamus is derived from the *Gbx2* lineage (Chen et al., [@B15]). Around midgestation, however, *Gbx2* expression becomes restricted to a thalamic region including mostly the neurons of the medial and intralaminar group (Lein et al., [@B49]). We show that *Gbx2* expression is severely reduced in the *Gli3^Xt/Xt^* mutant at E12.5. In keeping with this reduction, the medial and intralaminar nuclei appear to be almost absent in the *Gli3^Xt/Xt^* mutant thalamus. It would also be possible that the development of the medial and intralaminar nuclei is rescued in the *Gli2^zfd/zfd^* mutant by Gli3A. However, since other rostral thalamic nuclei are affected in the *Gli2^zfd/zfd^* mutant, and the medial and intralaminar nuclei are not affected in mutants deficient in neuroepithelial Shh (Szabo et al., [@B99]), we do not think that a Gli3 activator function is at work here.

These data indicate that thalamic specification depends not only on the Shh pathway but rather on the interplay between this and other signaling systems like the Wnt and Fgf8 pathways (Zhou et al., [@B120]; Kataoka and Shimogori, [@B43]; Bluske et al., [@B11]; Martinez-Ferre and Martinez, [@B56]; Quinlan et al., [@B74]), possibly even in cooperation (Rash and Grove, [@B78]). Since, as we show, expression of transcriptional repressor *Hes1*, a Notch effector, specifically labels a thalamic nuclear group at E18.5 (see also Lein et al., [@B49]), the Notch pathway is also a candidate to be involved in thalamic specification and differentiation. Additionally, all or some of these pathways could act through regulating the activity of proneural genes (Scholpp et al., [@B86]).

Shh vs Gli3 in the dorsal diencephalon: A thalamic prepattern?
--------------------------------------------------------------

Shh downregulates Gli3R by preventing the processing of full-length Gli3A by the proteasome into a Gli3R form (Marigo et al., [@B54]; Ruiz i Altaba, [@B80]; Wang et al., [@B106]; Kise et al., [@B46]). In mutants deficient in both Shh signaling and Gli3, ventral patterning defects observed in *Shh* null mutants are partially rescued in the spinal cord and in the telencephalon (Litingtung and Chiang, [@B51]; Rallu et al., [@B76]; Wijgerde et al., [@B109]), indicating that one important function of Shh is to antagonize the formation of Gli3R. The concept of a "prepattern" has emerged, i.e., a pattern of the neural tube independent of *Shh* and *Gli3* (Ruiz i Altaba et al., [@B82]).

Deleting *Shh* in a *Gli3^Xt/Xt^* background, however, does not fully rescue the *Gli3^Xt/Xt^* phenotype in the telencephalon (Aoto et al., [@B1]; Persson et al., [@B71]; Rash and Grove, [@B77]; Yu et al., [@B116]). Moreover, in the midbrain or cerebellum, mutants with inactive Gli3 and inactive Shh signaling have a phenotype that is almost indistinguishable from Gli3 mutants, suggesting that the antagonistic function of Shh and Gli3 is not reciprocal (Blaess et al., [@B10]). Here we show that in the dorsal diencephalon the removal of Shh from the neuroepithelium in Gli3 mutants does not rescue the *Gli3^Xt/Xt^* phenotype, and even results in a much more severe phenotype. If we consider that the double mutant allows us to define for the first time the prepattern of the thalamus, that is, a pattern existing before any influence of Gli3 or neuroepithelial Shh, this prepattern would only include a rough rostro-caudal and dorso-ventral axis specification, overgrowth and partial specification of the medial pronuclear group as well as thalamocortical axonal extension.

The fact that the ventral component of the medial group (expressing *Gbx2*, *Lhx2*, and *Calb2*) seems to be not only present but is abnormally large in the double mutant, suggests that neuroepithelial Shh and Gli3 restrict the expansion of a specific progenitor pool in the medial region of the thalamic neuroepithelium (see below). In general, the increased size of the double mutant suggests that *Gli3* and neuroepithelial *Shh* cooperatively reduce the growth of the thalamic region. This is in agreement with the increase in proliferation in the spinal cord of the Gli2/Gli3 double mutants that has been linked to changes in the cell cycle (Bai et al., [@B6]).

The electroporation experiments blocking Shh and Gli3 at E12.5 on a wild type background show a reduction in cell number, i.e., the opposite effect as in the mutant. Therefore, blocking all Gli-mediated transcriptional regulation *per se* does not result in increased growth. This suggests that the factor or factors responsible for the prepattern act would act early, in a defined time-window. Their effect is therefore stage-specific.

Shh from the prechordal plate, which is intact in the *n-Shh/Gli3* double mutants (since it is intact in the *n-Shh* mutants;Szabo et al., [@B98]) could be responsible for the patterning of the *n-Shh/Gli3* mutant thalamus, as well as the Fgf8, Wnt and maybe Notch pathways (see above).

Conclusion
==========

We have analyzed for the first time the relation between Shh, GliA, and GliR in a dorsal portion of the mouse nervous system, the thalamus. We show that Shh acts upstream of GliA in the specification of pattern and size of most thalamic nuclei (except the medial and intralaminar groups). In a complementary manner, GliR is essential for specification and growth of the medial and intralaminar nuclei (although it also contributes to the specification of other thalamic nuclei and to restrict thalamic size). Additionally, we have found that if Gli2A is abolished, Gli3A can partially substitute for it in the thalamus. Finally, and against what has been established in ventral regions of the neural tube, GliA (from neuroepithelial Shh signaling) and GliR are not reciprocally antagonistic in the thalamus.
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ATN, anterior thalamic nuclei (central pronucleus); CL, centrolateral nucleus (medial pronucleus); CM, centromedial nucleus (medial pronucleus); LG/LGN, lateral geniculate nucleus; LGd/LGNd, lateral geniculate nucleus (dorsal); LP, lateral posterior nucleus (dorsal pronucleus); MD, mediodorsal nucleus (medial pronucleus); MG/MGN, medial geniculate nucleus; MV, medioventral nucleus (reuniens; medial pronucleus); PO, posterior nucleus (dorsal pronucleus); PT, paratenial nucleus (medial pronucleus); PTh, prethalamus; PV, thalamic paraventricular nucleus; STN, subthalamic nucleus; Th, thalamus; TL, telencephalon; VM, ventromedial nucleus (central pronucleus); VP, ventral posterior nucleus (central pronucleus); ZLI, zona limitans interthalamica.
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